Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
Oncology Pharma Inc. (OTC PINK:ONPH) is advancing its Co-Development plan focused on new drug formulations for pediatric cancer treatment. The company is developing a dactinomycin nanoemulsion to enhance targeted delivery and minimize overall costs and time to market. A meeting is scheduled for November with the Board and advisors to discuss ongoing data, license agreements, and commercialization. However, the company faces potential risks including negative cash flow, funding needs, and uncertainties in market acceptance.
- Progress in developing a dactinomycin nanoemulsion drug product for pediatric cancer treatment.
- Focus on reducing costs and timelines for drug commercialization.
- Current negative operating cash flows and a need for additional funding.
- Risks related to licensing agreements and potential failures to realize business benefits.
- Volatility in operating results and financial condition.
SAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing its primary goal of the Co-Development plan to bring new pharmaceutical drug formulations to market with a focused approach that aims to reduce overall costs and minimize time and duration to commercialization.
The Company has developed the framework for early feasibility and initial non-clinical studies; and is in the process of creating data that focuses on using a dactinomycin nanoemulsion drug product, intended for the treatment of pediatric cancer. Dactinomycin has been shown to be effective in destroying cancer cells. Utilizing the nanoemulsion for the targeted delivery system is expecting to allow a safe dose of the drug to be delivered over time, so it may be safely administered.
The Company is further planning on a November meeting with its Board of Directors, Scientific Advisory Board, Co-Development Partners and other advisors to discuss and present the ongoing data development, status of license agreements, commercialization and any further developments with its partner companies.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD-LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/669937/Oncology-Pharma-Inc-Gives-Update-on-Ongoing-Work-and-Progress
FAQ
What is Oncology Pharma's recent development in pediatric cancer treatment using ONPH?
When is the next meeting for Oncology Pharma's Board of Directors?
What are the financial risks mentioned in Oncology Pharma's press release?
How does Oncology Pharma aim to reduce costs in drug formulation?
What is the significance of the dactinomycin nanoemulsion for Oncology Pharma?
